Crossref
Clinical Spectrum and Therapeutic Options in Monogenic CTLA-4-, LRBA-, or SOCS1-Related Primary Immune Regulatory Disorders
The Journal of Allergy and Clinical Immunology: In Practice · 2026-07 · 14 (7) · 1489-1490
DOI: 10.1016/j.jaip.2026.06.004 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2026-07.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
(2026). Clinical Spectrum and Therapeutic Options in Monogenic CTLA-4-, LRBA-, or SOCS1-Related Primary Immune Regulatory Disorders. The Journal of Allergy and Clinical Immunology: In Practice, 14(7), 1489-1490. https://doi.org/10.1016/j.jaip.2026.06.004
Vancouver
Clinical Spectrum and Therapeutic Options in Monogenic CTLA-4-, LRBA-, or SOCS1-Related Primary Immune Regulatory Disorders. The Journal of Allergy and Clinical Immunology: In Practice. 2026;14(7):1489-1490. doi:10.1016/j.jaip.2026.06.004
BibTeX
@article{euvimed2026,
title = {Clinical Spectrum and Therapeutic Options in Monogenic CTLA-4-, LRBA-, or SOCS1-Related Primary Immune Regulatory Disorders},
journal = {The Journal of Allergy and Clinical Immunology: In Practice},
year = {2026},
volume = {14},
number = {7},
pages = {1489--1490},
doi = {10.1016/j.jaip.2026.06.004}
}
EUVIMED